Clinical Trial Update: ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME

View source ↗

Summary

A ClinicalTrials.gov update indicating the study assessing Emerald and MC10 BioStamp nPoint biosensors for Rett syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Snippet

Sponsor: Rett Syndrome Research Trust | Conditions: Rett Syndrome | Status: COMPLETED